WO2009005045A1 - Dérivé de dihydroisoquinoléine substituée - Google Patents

Dérivé de dihydroisoquinoléine substituée Download PDF

Info

Publication number
WO2009005045A1
WO2009005045A1 PCT/JP2008/061876 JP2008061876W WO2009005045A1 WO 2009005045 A1 WO2009005045 A1 WO 2009005045A1 JP 2008061876 W JP2008061876 W JP 2008061876W WO 2009005045 A1 WO2009005045 A1 WO 2009005045A1
Authority
WO
WIPO (PCT)
Prior art keywords
acceptable salt
pharmacologically acceptable
pharmaceutical agent
intracellular signaling
dihydroisoquinoline derivative
Prior art date
Application number
PCT/JP2008/061876
Other languages
English (en)
Japanese (ja)
Inventor
Shoichi Saito
Yukari Onishi
Junko Sasaki
Taketoshi Ogawa
Shiho Kozuma
Osamu Ando
Original Assignee
Daiichi Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Company, Limited filed Critical Daiichi Sankyo Company, Limited
Publication of WO2009005045A1 publication Critical patent/WO2009005045A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur un dérivé de dihydroisoquinoléine substituée qui peut inhiber une signalisation intracellulaire ou une activation cellulaire induite par une endotoxine ou une réponse cellulaire (par exemple la production en excès d'un médiateur inflammatoire) induite par la signalisation intracellulaire ou l'activation cellulaire, ou sur un sel pharmacologiquement acceptable de ce dérivé ; un agent pharmaceutique comprenant le dérivé de dihydroisoquinoléine substituée ou le sel pharmacologiquement acceptable de ce dérivé comme ingrédient actif ; un procédé de fabrication du dérivé de dihydroisoquinoléine substituée ou du sel pharmacologiquement acceptable de ce dérivé ou de l'agent pharmaceutique ; et un agent pharmaceutique utile pour la prévention et/ou le traitement d'une maladie associée avec une signalisation intracellulaire ou une activation cellulaire induite par une endotoxine ou une réponse cellulaire induite par la signalisation intracellulaire ou l'activation cellulaire, tel que la sepsis (comprenant le choc septique, la coagulation intravasculaire disséminée, la défaillance d'organes multiples), qui comprend le dérivé de dihydroisoquinoléine substituée comme ingrédient actif. De façon spécifique, l'invention porte sur un composé représenté par la formule générale (I) ou un sel pharmacologiquement acceptable de ce dérivé ; et sur un agent pharmaceutique comprenant le composé comme ingrédient actif.
PCT/JP2008/061876 2007-07-04 2008-07-01 Dérivé de dihydroisoquinoléine substituée WO2009005045A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007175959 2007-07-04
JP2007-175959 2007-07-04

Publications (1)

Publication Number Publication Date
WO2009005045A1 true WO2009005045A1 (fr) 2009-01-08

Family

ID=40226089

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/061876 WO2009005045A1 (fr) 2007-07-04 2008-07-01 Dérivé de dihydroisoquinoléine substituée

Country Status (2)

Country Link
TW (1) TW200914012A (fr)
WO (1) WO2009005045A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012063099A1 (fr) 2010-11-08 2012-05-18 Telefonaktiebolaget L M Ericsson (Publ) Procédé et appareil permettant le réacheminement de dns dans des systèmes de télécommunication mobile

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11147876A (ja) * 1997-09-12 1999-06-02 Kanebo Ltd テトラヒドロイソキノリン誘導体およびそれを有効成分とする薬剤
JP2001518090A (ja) * 1997-03-28 2001-10-09 ゼネカ リミテッド 腫瘍壊死因子の阻害に有用な複素環により置換したヒドロキサム酸

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001518090A (ja) * 1997-03-28 2001-10-09 ゼネカ リミテッド 腫瘍壊死因子の阻害に有用な複素環により置換したヒドロキサム酸
JPH11147876A (ja) * 1997-09-12 1999-06-02 Kanebo Ltd テトラヒドロイソキノリン誘導体およびそれを有効成分とする薬剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HARSANYI K. ET AL.: "Isobasic isoquinolines. I. Derivatives of 2- (hydroxyimino)-2-(1-isoquinolinyl)acetic acid and their reduction products", JUSTUS LIEBIGS ANNALEN CHEMIE, vol. 10, 1973, pages 1606 - 1611 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012063099A1 (fr) 2010-11-08 2012-05-18 Telefonaktiebolaget L M Ericsson (Publ) Procédé et appareil permettant le réacheminement de dns dans des systèmes de télécommunication mobile

Also Published As

Publication number Publication date
TW200914012A (en) 2009-04-01

Similar Documents

Publication Publication Date Title
WO2007135527A3 (fr) Composés de benzimidazolyle
WO2008001195A3 (fr) Nouveaux procédés de synthèse d'inhibiteurs de dpp iv
TW200728307A (en) Novel spirochromanone derivatives
WO2008110314A8 (fr) Fluoroalkylphénylamidines et leur utilisation comme fongicides
WO2006121941A3 (fr) Compositions pharmaceutiques comprenant l'imatinibe et un retardateur de liberation
WO2008005368A3 (fr) Pipérazines en tant qu'antagonistes de p2x7
WO2007117465A3 (fr) Composés d'indazole
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
WO2010136474A3 (fr) Dérivés aminobutyriques substitués en tant qu'inhibiteurs de néprilysine
WO2008048867A3 (fr) Composés hétoroaromatiques bicycliques
WO2006113552A8 (fr) Cyanoarylamines
WO2008022286A3 (fr) petits inhibiteurs moléculaires de la kynurénine-3-monooxygénase
NO20090075L (no) Nye CXCR2 inhibitorer
WO2009060835A8 (fr) Nouvelle petite molécule de liaison de l'ubiquitine
EP1704856A4 (fr) Inhibiteur de proteines de la famille hsp90
WO2008059370A3 (fr) Composés bicyclocarboxyamides substitués
WO2007126900A3 (fr) Agents antifongiques
MX2009010302A (es) Derivados de indol que tienen actividad inhibidora de cpla2 y aplicaciones y metodos de produccion.
EA201270359A1 (ru) Терапевтическое средство от расстройств настроения
WO2007023342A3 (fr) Processus de fabrication d'acides bisphosphoniques gemines et de sels et/ou d'hydrates de ceux-ci repondant aux normes pharmaceutiques
WO2008155666A3 (fr) Dérivés de pyrimidone hétéroarylamide
WO2008153129A1 (fr) Agent pour abaisser le taux d'acide urique
EP1650194A4 (fr) Inhibiteur de la proteine kinase
MX2013007937A (es) Nuevo derivado de indol o indazol o sal del mismo.
WO2009040952A1 (fr) Médicament renfermant un dérivé de benzophénone ou son sel

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08777727

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08777727

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP